Clinical Trial Update: Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a recombinant Mycobacterium tuberculosis fusion protein for latent tuberculosis infection in adults aged 65 and older; current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Latent Tuberculosis Infection

Drugs mentioned

• Recombinant Mycobacterium Tuberculosis Fusion Protein

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Latent Tuberculosis Infection | Phase 3 | Status: RECRUITING